The pharmacist Eli Lilly It announced on Thursday (17) that an experimental version of the popular GLP-1 tablets-such as Mounjaro-helped people with type 2 diabetes lose almost 8% of body weight after 40 weeks and reduced their levels of glycated hemoglobin.
Lilly, which is a Mounjaro manufacturer, a diabetes treatment medicine, is among several companies looking for an effective way in LPG-1 analog pills. The only tablet available so far comes with strict dietary restrictions.
Lilly’s announcement takes place shortly after a Pfizer statement, which said on Monday (14) that she was ending the development of her daily treatment in obesity. A patient in the clinical trial had a possible liver injury that was no longer a problem after using the drug, according to Pfizer.
In 2020, the US regulatory agency Food and Drug Administration (FDA) approved the new Nordisk Rybelsus for Type 2 diabetes treatment, but should be taken with an empty stomach. Some doctors also report that Rybelsus may not be as effective as injections, but still has side effects.
Lilly states that such dietary restrictions are not required with its experimental oral drug, orforglipron, and that it is the first type to complete a phase 3 test.
The Indianapolis company said that in a study of more than 550 people, Orforglipron reduced weight by average 7.2 kg (7.9%) among people who had type 2 diabetes with inappropriate glycemic control with diet and exercise only, and were using the highest dose of the drug. Participants were still losing weight at the end of the 40 -week rehearsal.
The study also achieved its primary goal of reducing the level of glycated hemoglobin of participants – a measure of the average amount of blood glucose in the previous three months – more than a placebo. Participants saw an average reduction of 1.3% to 1.6% of an 8% base line.
Glucose, or blood sugar, is the main source of energy of the body. People with diabetes cannot produce enough insulin, a hormone that the pancreas produces to help the body maintain blood sugar levels in a certain range. People with type 2 diabetes may also have cells resistant to the effects of insulin.
GLP-1 medications help control blood sugar by stimulating the pancreas to release insulin and suppressing the release of another hormone. LPG-PAs also help reduce the feeling of hunger and can make people feel more time.
Orforglipron helped more than 65% of the test participants reach or maintain their A1C by 6.5% or less, the level at which people are considered diabetic, Lilly said.
Dan Skovronsky, Lilly’s scientific director, said on Wednesday that even before the rehearsal results were released within the company, he knew they would be good. “When I entered the room to see the results, I saw everyone smiling, so I knew they were about to share good news with me,” he said.
Liver injury such as that was seen in Pfizer’s drug test is always possible with small molecule medications like this, Skovronsky said, and it is difficult to detect if it will cause a problem until the medicine is tested on enough people. “We didn’t see a sign of liver security with ours, which was a relief,” said Skovronsky.
The side effects with the tablet were similar to those reported with injectable forms of GLP-1 medicines. Adverse events were considered generally mild to moderate, according to the company, and the stomach malaise is most commonly reported.
Many people who use injecting LPG-1s end up giving up due to side effects. But at the end of this rehearsal, Skovronsky said more than 90% of participants continued with the medicine.
LPG-1 injections are highly effective, but for many people, they are prohibitively expensive. The injections are also complicated and expensive to produce.
A daily tablet would be easier to use and, being cheaper to manufacture, could possibly reduce costs for patients, experts say. It is too early to know how much Orforglipron can cost if approved.
Injectable medications also have other disadvantages. They need to be refrigerated and require plastic applicators, while tablets have less packaging.
“Pill -shaped drugs are valuable for many patients for various reasons, particularly for those who have needles phobia,” said Dr. Amy Rothberg, clinical professor of medicine in the Metabolism, Endocrinology and Diabetes Division of the Department of Internal Medicine and a researcher of nutritional science at the University of Michigan School of Public Health. “And probably simplifies things by just adding another tablet rather than taking an injection, which is a little more complex.”
Access to medicines that need to be taken for a long time is critical, said Dr. Priya Jaisinghani, an endocrinologist who works with obesity medicine at Nyu Langone Health.
“As clinicians, our priority is to align treatment with our patients’ preferences to promote long -term adherence,” said Jalismhani, who is also a clinical assistant professor at the NYU Department of Medicine School of Medicine and who has not participated in the new research. “For patients who may find injecting injecting or undesirable therapies, an oral alternative can facilitate both the beginning and the continuation of therapy.”
Rothberg, who has not participated in the new study, expects Lilly to transfer cost savings to patients if the drug is approved.
A growing number of people need treatment for diabetes or obesity. More than 40% of US adults live with obesity, and about 11.6% of the population – estimated 38.4 million Americans – had been diagnosed with diabetes by 2021, according to US disease control and prevention centers. Most have type 2 diabetes.
Skovronsky said Lilly is already producing Orforglipron tablets after getting prior promising results, assuming that the rest of the tests will go well. “Thus, we will have adequate supply to meet the demand,” he said.
Lilly plans to publish the results of its final stages in a peer -reviewed scientific journal and hopes to share more results later this year, along with discoveries from another clinical trial program that created to evaluate the medicine regarding its weight control qualities. You are also testing to see if a tablet can improve people’s high blood pressure and sleep apnea, two conditions that have been helped with injectable LPG-1s.
Lilly said she hopes to request the approval of Orforglipron for weight control by the end of the year and present results about her treatment for type 2 diabetes.
United Kingdom studies Mounjaro to make people go back to work
This content was originally published in a new weight loss pill reduces up to 8% of the weight, says pharmacist on CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
